Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment

被引：383

作者：

Sniderman, AD

Furberg, CD

Keech, A

van Lennep, JER

Frohlich, J

Jungner, I

Walldius, G

机构：

[1] McGill Univ, McGill Univ Hlth Ctr, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ, Canada

[2] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA

[3] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia

[4] Leiden Univ, Med Ctr, Leiden, Netherlands

[5] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada

[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[7] St Gorans Univ Hosp, CALAB Res, Stockholm, Sweden

[8] Karolinska Inst, Karolinska Hosp, Clin Epidemiol Unit, S-10401 Stockholm, Sweden

[9] AstraZeneca, Molndal, Sweden

[10] Karolinska Inst, King Gustaf V Res Inst, Stockholm, Sweden

来源：

LANCET | 2003年 / 361卷 / 9359期

关键词：

D O I：

10.1016/S0140-6736(03)12663-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：777 / 780

页数：4

共 17 条

[1] Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme a reductase inhibitors on non-high-density lipoprotein cholesterol levels
Ballantyne, CM
Andrews, TC
Hsia, JA
Kramer, JH
Shear, C
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (03) : 265 - 269
[2] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Cleeman, JI
Grundy, SM
Becker, D
Clark, LT
Cooper, RS
Denke, MA
Howard, WJ
Hunninghake, DB
Illingworth, DR
Luepker, RV
McBride, P
McKenney, JM
Pasternak, RC
Stone, NJ
Van Horn, L
Brewer, HB
Ernst, ND
Gordon, D
Levy, D
Rifkind, B
Rossouw, JE
Savage, P
Haffner, SM
Orloff, DG
Proschan, MA
Schwartz, JS
Sempos, CT
Shero, ST
Murray, EZ
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
[3] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[4] Durrington PN, 2002, CLIN CHEM, V48, P401
[5] Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Gotto, AM
Whitney, E
Stein, EA
Shapiro, DR
Clearfield, M
Weis, S
Jou, JY
Langendörfer, A
Beere, A
Watson, DJ
Downs, JR
de Cani, JS
[J]. CIRCULATION, 2000, 101 (05) : 477 - 484
[6] Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study
Lamarche, B
Moorjani, S
Lupien, PJ
Cantin, B
Bernard, PM
Dagenais, GR
Despres, JP
[J]. CIRCULATION, 1996, 94 (03) : 273 - 278
[7] Miremadi S, 2002, CLIN CHEM, V48, P484
[8] Thrombogenic factors and recurrent coronary events
Moss, AJ
Goldstein, RE
Marder, VJ
Sparks, CE
Oakes, D
Greenberg, H
Weiss, HJ
Zareba, W
Brown, MW
Liang, CS
Lichstein, E
Little, WC
Gillespie, JA
Van Voorhees, L
Krone, RJ
Bodenheimer, MM
Hochman, J
Dwyer, EM
Arora, R
Marcus, FI
Watelet, LFM
Case, RB
[J]. CIRCULATION, 1999, 99 (19) : 2517 - 2522
[9] Otvos JD, 2002, AM J CARDIOL, V90, p22I
[10] Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study
Pedersen, TR
Olsson, AG
Færgeman, O
Kjekshus, J
Wedel, H
Berg, K
Wilhelmsen, L
Haghfelt, T
Thorgeirsson, G
Pyörälä, K
Miettinen, T
Christophersen, B
Tobert, JA
Musliner, TA
Cook, TJ
[J]. CIRCULATION, 1998, 97 (15) : 1453 - 1460

← 1 2 →